Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
January 2014—ViroStat has released three new monoclonal antibodies that have broad reactivity with several rhinovirus types. These antibodies are reactive with the VP3 capsid protein and function in ELISA and IFA to detect these viruses. Data sheets for these antibodies are available from the company.
January 2014—Immunetics introduced an updated BacTx analyzer for use with its BacTx rapid test for bacteria in whole blood–derived and apheresis platelets. The analyzer offers automated interpretation, tracking, and documentation.
January 2014—AION Laboratories, a division of PAML, has been established to provide a full spectrum of laboratory testing to age-management physicians and clinics across the country. AION’s aging-related tests use a single requisition to obtain a thorough laboratory assessment of each patient.
January 2014—Terumo BCT has been awarded a U.S. Department of Defense cost-share contract worth up to $29.9 million to advance the Mirasol system for the treatment of donated whole blood used in emergency transfusions to deployed military personnel.
January 2014—Chembio Diagnostics received its first purchase order for its DPP HIV-Syphilis Assay from its distributor in Mexico. The DPP HIV-Syphilis Assay is based on the company’s patented Dual Path Platform (DPP), a point-of-care testing platform that is suited to multiplexing and that adds a syphilis biomarker to the company’s FDA-approved DPP HIV 1/2 test. The addition of this marker has resulted in a fingerstick whole blood test that can help reduce the transmission of HIV and syphilis from mother to child.
January 2014—Enzo Life Sciences has expanded its portfolio of drug discovery platforms with the introduction of the new Leading Light Sclerostin-LRP Screening System. Developed to meet the market need for a simple, sensitive biochemical screening assay for detection of sclerostin inhibitors (antagonists of the Wnt signaling pathway), this kit is a drug discovery tool for detecting small molecule inhibitors that disrupt the interaction between SOST and LRP5.
January 2014—Diagnostic BioSystems introduces a new chromogen to its color spectrum, PermaRed/HRP. This HRP-based substrate/chromogen system produces a sharp, contrasting brick red color.
January 2014—With the recent acquisition by Nuclea Biotechnologies of Wilex (Oncogene Science), Nuclea will begin its foray into the GMP manufacturing and marketing of the FDA 510(k)-cleared HER2/neu blood test out of its facility in Cambridge, Mass. The test is available as an in vitro diagnostic in the U.S., Canada, and Europe (CE mark).
January 2014—Royal Philips received 510(k) clearance from the FDA to market its HER2/neu IHC Digital Manual Read product in the U.S.
January 2014—Rainbow Scientific is offering advanced research products for human mesenchymal stem cell (hMSC) and human embryonic stem cell (hESC) culture from Biological Industries.
